Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: evidence for reversal of joint damage

✍ Scribed by Barry M. Weichman; Thuy T. Chau; George Rona

• Publisher: John Wiley and Sons
• Year: 1987
• Tongue: English
• Weight: 582 KB
• Volume: 30
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.1780300419

✦ Synopsis

Histopathologic evaluation of hindpaws from control rats with established adjuvant arthritis showed severe alterations in soft tissue and bone, as well as progressive, moderate-to-severe articular changes. Following treatment with etodolac for 28 days, soft tissue and articular changes were rated mild, and bone changes were rated moderate, but with remodeling. These findings indicate that etodolac partially reversed the joint damage in these rats.

Etodolac (Ultradol) is an antiinflammatory, antiarthritic drug that possesses the chemically distinct tetrahydropyranoindole-acetic acid structure (1). Clinical efficacy has been established in patients with rheumatoid arthritis (2), osteoarthritis (3), and postsurgical pain (4). Recently, in patients with active rheumatoid arthritis, etodolac has been shown to retard the radiographic progression of the disease in the hand and wrist, whereas aspirin did not (5).

Limb swelling, inflammatory cell infiltration, proliferative synovitis, subcutaneous nodules, and erosion of the cartilage and bone structures represent common modalities between human arthritis and rat adjuvant arthritis (6). While most nonsteroidal anti-From the